Apixaban IR + Apixaban MR1 + Apixaban MR2 + Apixaban MR3
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Thrombosis
Conditions
Thrombosis
Trial Timeline
Jun 1, 2009 → Aug 1, 2009
NCT ID
NCT00914641About Apixaban IR + Apixaban MR1 + Apixaban MR2 + Apixaban MR3
Apixaban IR + Apixaban MR1 + Apixaban MR2 + Apixaban MR3 is a phase 1 stage product being developed by Pfizer for Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00914641. Target conditions include Thrombosis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00914641 | Phase 1 | Completed |
Competing Products
20 competing products in Thrombosis